Dear reader,
This issue of Human Vaccines & Immunotherapeutics starts with a section on the Coronavirus: three reviews highlight the way SARS-CoV-2 genomics and immunopathology guide vaccine development (Abdullahi, p 620), the role of the thymus in Covid-19 disease severity (Kellogg, p 638), and vaccines in clinical and preclinical development (Li, p 644). Three commentaries further discuss neutralizing antibody responses elicited by the viral receptor-binding domain (Huang, p 654), trial design during the pandemic (Jiang, p 656), and potential impact of the pandemic on routine vaccination programs (Ogundele, p 661).
Six articles on Influenza include a survey of seasonal vaccine coverage among healthcare workers in Germany (Neufeind, p 664), an estimate of impact of a manual for vaccine interventions on acceptance in long-term care facilities (Boey, p 673), a Phase 3 immunogenicity and safety trial of a split-virion quadrivalent vaccine in healthy children (Sarkar, p 681), safety trial of an inactivated quadrivalent vaccine (Thiem, p 690), and a Letter to the Editor on vaccine cost-effectiveness calculation (Alvarez, p 694) with a Response Letter (Ruiz-Aragón, p 696).
The Licensed Vaccines segment features an assessment of measles epidemiology and surveillance in the US (McKay, p 698), a report on underdiagnosed severe pertussis in infants (Di Camillo, p 705), a meta-analysis of the rate of adverse events following rabies vaccination in China (Li, p 714), a Phase 3 trial of a reduced-antigen-content DTaP vaccine as a booster dose (Asatryan, p 723), an article on the impact of the inclusion of varicella vaccine in the immunization schedule on varicella and zoster incidence in Turkey (Soysal, p 731), modelling of optimal vaccination strategy in response to a potential bioterrorism attack (Costantino, p 738), characterization of the anthrax vaccine (Modi, p 747), and a meeting report from the Tipico X workshop on infectious diseases and vaccines (Rivero-Calle, p 759).
Four Acceptance articles report on willingness to accept and pay for a dengue vaccine in Bangladesh (Kabir, p 773), vaccine knowledge and attitudes of Muslim parents in Malaysia (Ansari, p 785), predictors of vaccine uptake among HIV patients in a specialty care clinic (Johnson, p 791), and caregivers’ satisfaction with infant vaccination in Ethiopia (Dana, p 797).
Four research articles on Public Health investigate the impact of outbreak on vaccine attitudes (Talarek, p 805), trends in vaccination inequities in small Chinese children (Hu, p 810), vaccine coverage among pediatric onco-hematological patients (Giordano, p 818), and a reporting tool for vaccine waste reduction in India (Rustagi, p 824).
The HPV section offers a survey of vaccine knowledge and attitudes among Chinese college students (Deng, p 828), a commentary on vaccination in Japan during the coronavirus pandemic (Miyoshi, p 836), and a report on the virus epidemiology HIV-positive women in Brazil (Haddad Kury, p 838).
Research articles on Hepatitis study look into the long-term serostatus against HBV in an endemic region (Zheng, p 845), subjects who remain antibody-negative after HBV vaccination (Yoda, p 852), and trends in publication on HEV (Ahmad, p 857).
The Rotavirus section includes reviews of vaccine coverage and completion in the US (Ghaswalla, p 872), and the effectiveness of existing and newly developed vaccines (Wang, p 880).
The Novel Vaccines section features a review of bacterial extracellular vesicles and their potential use in vaccine development (Peng, p 897), and a commentary on vaccines against Zika virus (Lunardelli, p 904).
Finally, we present a study on the cost-effectiveness of a national vaccination program with the 13- and 10-valent Pneumococcal conjugate vaccines in South Korea (Kim, p 909), and a safety and immunogenicity trial of a Meningococcal polysaccharide vaccine against serogroups A and C in children (Zhu, p 919).
Our monthly News, Policy and Profiles (NP&P) track offers a selection of the latest news in the field of vaccines and immunotherapeutics. In this section we also regularly publish opinion pieces on timely, interesting and controversial topics related to vaccines and immunotherapeutics, profiles of companies and organizations, as well as portraits of distinguished scientists in our field. Please contact Acquisitions Editor Adam Weiss ([email protected]) with your ideas for commentaries, opinion pieces, profiles and portraits. Your suggestions for and contributions to our N&P&P track are always welcome!
Sincerely,
Ronald Ellis, PhD
Editor-in-Chief
Adam Weiss, PhD
Acquisitions Editor